{"id":"NCT00868959","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression","officialTitle":"A 24-Week, Flexible-Dose, Open-Label Extension Study of Lurasidone for the Treatment of Bipolar I Depression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04","primaryCompletion":"2013-02","completion":"2013-02","firstPosted":"2009-03-25","resultsPosted":"2014-04-01","lastUpdate":"2016-04-14"},"enrollment":817,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Depression"],"interventions":[{"type":"DRUG","name":"lurasidone","otherNames":[]}],"arms":[{"label":"lurasidone","type":"EXPERIMENTAL"}],"summary":"This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression","primaryOutcome":{"measure":"Number of Participants With Serious and Non-serious Treatment-emergent Adverse Events Who Have Completed 24 Weeks of Extension Study Treatment","timeFrame":"24 weeks","effectByArm":[{"arm":"Lurasidone","deltaMin":529,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":151,"countries":["United States","Canada","Colombia","Czechia","France","India","Japan","Lithuania","Peru","Poland","Romania","Russia","Slovakia","South Africa","Ukraine"]},"refs":{"pmids":["29146409"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":813},"commonTop":["Akathisia","Headache","Nausea","Insomnia","Anxiety"]}}